Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 12Phase 3 10Phase 1/2 3Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Pancreatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 9Neoplasms 6Lung Neoplasms 5Neoplasm Metastasis 4Colorectal Neoplasms 4Breast Neoplasms, Male 4Squamous Cell Carcinoma of Head and Neck 3Melanoma 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Inflammatory Breast Neoplasms 2Carcinoma, Ovarian Epithelial 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor 1Platinum-Refractory Fallopian Tube Carcinoma 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms, Basal Cell 1Neoplasms by Site 1Neoplasms by Histologic Type 1

Interventions

Carboplatin 23Paclitaxel 14pembrolizumab 8liposomal doxorubicin 7Bevacizumab 5Specimen Handling 4olaparib 3niraparib 3epacadostat 3Topotecan 3Taxes 3Nivolumab 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Cyclophosphamide 3Biopsy 3sarilumab 2rucaparib 2poly ICLC 2durvalumab 2cemiplimab 2STA 9090 2Injections 2Immunoglobulin G 2Drug Therapy 2Docetaxel 2Disulfides 2Cisplatin 2veliparib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Fallopian Tube Neoplasms × Taxes × Clear all
NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT02713386 2025-05-25

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NRG Oncology

Phase 1/2 Completed
147 enrolled 18 charts
Gynecologic

Fallopian Tube Neoplasms

NCT01962948 2024-03-26

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Fox Chase Cancer Center

Phase 1/2 Terminated
12 enrolled 8 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡